<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Canadian Pharmacy Blog &#187; Asthma</title>
	<atom:link href="http://annpharmacy.com/blog/category/asthma/feed" rel="self" type="application/rss+xml" />
	<link>http://annpharmacy.com/blog</link>
	<description>Health, Diseases, Drugs &#38; medications, Online canadian pharmacy</description>
	<lastBuildDate>Wed, 25 May 2011 13:02:23 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
		<item>
		<title>Three Asthma Drugs to Stay on Market for Now</title>
		<link>http://annpharmacy.com/blog/asthma/three-asthma-drugs-to-stay-on-market-for-now.html</link>
		<comments>http://annpharmacy.com/blog/asthma/three-asthma-drugs-to-stay-on-market-for-now.html#comments</comments>
		<pubDate>Fri, 05 Nov 2010 05:34:34 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Asthma]]></category>
		<category><![CDATA[Asthma Drugs]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=802</guid>
		<description><![CDATA[A panel of lung experts met in July to advise the government whether three popular asthma drugs should remain on the market, be relabeled, or be taken off the market because of safety concerns. The FDA concluded that the drugs could be kept on the market but urged more research. GlaxoSmithKline&#8217;s fluticasone propi-onate/salmeterol drug (Advair® [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/asthma/three-asthma-drugs-to-stay-on-market-for-now.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Head-to-Head Study of Two Popular Treatments for Chronic Lung Disease</title>
		<link>http://annpharmacy.com/blog/asthma/head-to-head-study-of-two-popular-treatments-for-chronic-lung-disease.html</link>
		<comments>http://annpharmacy.com/blog/asthma/head-to-head-study-of-two-popular-treatments-for-chronic-lung-disease.html#comments</comments>
		<pubDate>Mon, 27 Sep 2010 08:31:52 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Asthma]]></category>
		<category><![CDATA[Lung Disease]]></category>
		<category><![CDATA[Popular Treatments]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=747</guid>
		<description><![CDATA[Although the combination treatments of salmeterol/fluticasone propionate (e.g., Generic Advair® Diskus, GlaxoSmithKline) and ipratropium/albuterol medication (Combivent drug, Boehringer Ingelheim) have been widely used to treat chronic obstructive pulmonary disease (COPD), only one published study has compared these agents head to head. Investigators from National Jewish Medical and Research Center in Denver, Baylor Col­lege of Medicine [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/asthma/head-to-head-study-of-two-popular-treatments-for-chronic-lung-disease.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Emergency Bronchodilators Less Beneficial for Elderly</title>
		<link>http://annpharmacy.com/blog/asthma/emergency-bronchodilators-less-beneficial-for-elderly.html</link>
		<comments>http://annpharmacy.com/blog/asthma/emergency-bronchodilators-less-beneficial-for-elderly.html#comments</comments>
		<pubDate>Wed, 08 Sep 2010 08:56:22 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Asthma]]></category>
		<category><![CDATA[Emergency Bronchodilators]]></category>
		<category><![CDATA[Less Beneficial]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=624</guid>
		<description><![CDATA[Researchers from Harvard University in Boston, Jewish General Hospital in Montreal, Summa Health System in Akron, and MetroHealth Medical Center in Cleveland have found that older patients may be less likely to benefit from bronchodilators in emergency departments (EDs). In a study of 2,064 patients with asthma, all age groups had severe exacerbations. Patients 55 [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/asthma/emergency-bronchodilators-less-beneficial-for-elderly.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Fluticasone for Young Children</title>
		<link>http://annpharmacy.com/blog/asthma/fluticasone-for-young-children.html</link>
		<comments>http://annpharmacy.com/blog/asthma/fluticasone-for-young-children.html#comments</comments>
		<pubDate>Tue, 07 Sep 2010 08:56:20 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Asthma]]></category>
		<category><![CDATA[Fluticasone]]></category>
		<category><![CDATA[Young Children]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=622</guid>
		<description><![CDATA[The FDA has approved drug fluticasone propionate (Flovent generic, GlaxoSmithKline) in asthmatic children 4 to 11 years of age. This inhaled corticosteroid helps prevent inflammation in the airways, one of the main components of asthma. Flovent HFA, a reformulation of Flo­vent Inhalation Aerosol, uses hydro-fluoroalkane (HFA-134a) to propel the medication out of the canister and [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/asthma/fluticasone-for-young-children.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ciclesonide Nasal Spray For Allergic Rhinitis</title>
		<link>http://annpharmacy.com/blog/asthma/ciclesonide-nasal-spray-for-allergic-rhinitis.html</link>
		<comments>http://annpharmacy.com/blog/asthma/ciclesonide-nasal-spray-for-allergic-rhinitis.html#comments</comments>
		<pubDate>Fri, 30 Jul 2010 16:32:22 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Asthma]]></category>
		<category><![CDATA[allergic rhinitis]]></category>
		<category><![CDATA[Nasal Spray]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=464</guid>
		<description><![CDATA[The FDA has approved ciclesonide nasal spray (Omnaris, Altana Pharma), a corticosteroid for treating nasal symptoms associated with seasonal and perennial allergic rhinitis (hay fever) in adults and in children 12 years of age and older. The precise mechanism of action is unknown, although corticosteroids suppress the immune response. requip 2 mg The safety and [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/asthma/ciclesonide-nasal-spray-for-allergic-rhinitis.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Boxed Warning to Be Added For Asthma Drug Omalizumab</title>
		<link>http://annpharmacy.com/blog/asthma/boxed-warning-to-be-added-for-asthma-drug-omalizumab.html</link>
		<comments>http://annpharmacy.com/blog/asthma/boxed-warning-to-be-added-for-asthma-drug-omalizumab.html#comments</comments>
		<pubDate>Thu, 08 Jul 2010 11:36:59 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Asthma]]></category>
		<category><![CDATA[Drug Omalizumab]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=393</guid>
		<description><![CDATA[Genentech has been instructed to add a boxed warning to its product label for omalizumab (Xolair), which is used to treat patients with asthma related to allergies. The warning emphasizes that this medication may cause anaphylaxis. The FDA has also asked Genentech to revise the label and provide a medication guide for patients to strengthen [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/asthma/boxed-warning-to-be-added-for-asthma-drug-omalizumab.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>SINGULAIR (Montelukast Sodium) Prevents Exercise-Induced Bronchoconstriction</title>
		<link>http://annpharmacy.com/blog/asthma/singulair-montelukast-sodium-prevents-exercise-induced-bronchoconstriction.html</link>
		<comments>http://annpharmacy.com/blog/asthma/singulair-montelukast-sodium-prevents-exercise-induced-bronchoconstriction.html#comments</comments>
		<pubDate>Sat, 02 Jan 2010 12:58:26 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Anti-Allergic]]></category>
		<category><![CDATA[Asthma]]></category>
		<category><![CDATA[allergic rhinitis]]></category>
		<category><![CDATA[Montelukast]]></category>
		<category><![CDATA[Singulair]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=138</guid>
		<description><![CDATA[It has been known today that generic Singulair is effective in preventing exercise-induced bronchoconstriction (EIB). According to the update facts by Merck &#38; Co., Inc. a new indication is useful in patients aged 15 years and older. The efficacy of SINGULAIR 10 mg was investigated in three randomized, double-blind, placebocontrolled crossover studies in 160 patients [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/asthma/singulair-montelukast-sodium-prevents-exercise-induced-bronchoconstriction.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

